Find a Physician | How to Contribute | Contact Us | Clinical Trials
Search: 
Select a Cancer Type:
Call 312-695-1102 with questions about Clinical Trials
Clinical Trials

Clinical Trial DRUG CMEK162AUS11

Title
Modular Phase II Study to Link Targeted Therapy to Patients with Pathway Activated Tumors: Module 3 - MEK162 for Patients with RAS/RAF/MEK Activated Tumors Local
Principal Investigator
Young Kwang Chae
Details
  • Status: CLOSED
  • Study Type: Therapeutic, Treatment
  • Protocol No:.DRUG CMEK162AUS11
Purpose
The purpose of this clinical trial is to study if MEK162 is safe and has beneficial effects in people who have different tumor types (cancer), and/or blood malignancies with a RAS/RAF/MEK activated pathway. This pathway is thought to play a role in tumor cell growth as well as in the growth of new blood vessels, which supply the tumor with nutrients and oxygen.
Overview
MEK162 is a drug that is being developed for the potential treatment of different tumor types and/or blood malignancies. MEK162 is a new type of drug that works by slowing down an important pathway (RAS/RAF/MEK) inside the cell involved in the development of certain types of cancers. This pathway (RAS/RAF/MEK) is thought to play a role in cell growth as well as in the growth of new blood vessels, which supply the tumor with nutrients and oxygen.
Eligibility
Some of the eligibility criteria include:
  • Study participants must have a confirmed diagnosis of a select solid tumor (except for pancreatic cancer, biliary cancer, colorectal cancer, low grade serous ovarian cancer, melanoma) or hematologic malignancy.
  • Participants must have had at least one prior treatment for cancer and it has returned (recurred) or it has spread beyond the initial cancer location (the cancer is metastatic and/or is locally advanced).
  • Participants must have cancer for which no standard therapy options are anticipated to result in a lasting remission.
  • Participants must have a tumor with a mutation in RAF, RAS, NF1 or MEK. This is determined by genetic testing.
Note: This is only a partial list of eligibility criteria. Please contact the Lurie Cancer Center for complete screening information if you are interested in this clinical trial.
Description of Treatment
In this study, a complete dosing cycle is 28 days. In each cycle, participants will take MEK162 twice a day, by mouth. Participants may continue to receive study drug unless they and/or the study doctor decide to stop the study drug dosing.
Contact
Sara Duffey
Clinical Research and Education Specialist
Robert H. Lurie Comprehensive Cancer Center
312.695.1102
cancertrials@northwestern.edu

Find Related Clinical Trials

Browse by Disease Sites

Other Clinical Trials by Young Kwang Chae

last updated: 18-Dec-14 07:26 AM

 

Clinical trial availability changes frequently. Please check this site often for updates or call 312.695.1102 for personal assistance.